Stonepine Capital Management’s BioAge Labs BIOA Stock Holding History

Stonepine Capital Management’s Portfolio BIOA Stock Details BIOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$490K	Sell	20,000 -30,000	-60%	-$542K	0.28%	64
2026 Q1	$875K	Buy	50,000 +5,000	+11%	+$96.3K	0.35%	43
2025 Q4	$595K	Sell	45,000 -143,571	-76%	-$1.27M	0.43%	47
2025 Q3	$1.11M	Buy	188,571 +37,486	+25%	+$176K	0.9%	24
2025 Q2	$624K	Buy	151,085 +101,085	+202%	+$407K	0.61%	37
2025 Q1	$188K	Buy	+50,000	New	+$231K	0.18%	50

Other funds holding BIOA

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Stonepine Capital Management's BIOA Position: Q2 2026 in Review

Stonepine Capital Management reduced its BioAge Labs (BIOA) stake by 60% in Q2 2026, selling an estimated $542K and leaving 20,000 shares worth $490K. The position accounts for 0.28% of the portfolio, ranked #64.

Stonepine Capital Management first reported a position in BIOA in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.11M in Q3 2025. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

Stonepine Capital Management held 20,000 shares of BioAge Labs worth $490K as of Q2 2026.
Stonepine Capital Management sold 30,000 BioAge Labs shares in Q2 2026, an estimated $542K.
BioAge Labs made up 0.28% of Stonepine Capital Management's portfolio in Q2 2026, its #64 holding.
Stonepine Capital Management first reported a position in BioAge Labs in Q1 2025 and has held it in 6 quarters since.
Stonepine Capital Management's BioAge Labs position peaked at $1.11M in Q3 2025.
151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.